The New KDOQI Guidelines for Anemia, a Debate: Should the Upper Hgb Limit be 12 or 13 g/dL?
Allen Nissenson, MD; Daniel Coyne, MD; Moderator: Brian Pereira, MD.
(ASN Renal Week Official Symposium, 2006).
Nissenson: What should the lower Hgb limit be? What do the May 2006 KDOQI guidelines recommend? What do the CPRs recommend regarding an upper limit?
What do CARI, the Canadians, and the Europeans recommend? Which clinical outcome may continue to improve at higher Hgb levels? What might be the benefits of raising the upper limit to 13? What would
be the potential risks? What did the Besarab and Parfrey RCTs show? What parts of CREATE and CHOIR are relevant to the debate? Coyne: Is a target between 11 and 12 too narrow? What is the
evidence that an upper level of > 13 may be associated with harm? Is there evidence that QOL is benefited at a target of 12-13 vs. a target of 11-12?
(more...)
|
New, Tri-Partite Approach to Anemia
John W. Adamson, MD; Stephen Fishbane, MD; Ajay K. Singh, MB, MRCP; (Moderator: Jay Wish, MD).
(ASN Renal Week Official Symposium, 2006). Adamson: What controls iron accumulation in the liver? What is hepcidin, and how do hepcidin knockouts or gain of function mutations affect gut
absorption of iron and release of iron from the RE system?
Fishbane: What happens to ferritin and TSAT as GFR falls? What was the thinking behind the upper ferritin limit of 500 ng/mL in the KDOQI Workgroup? How is reduced serum iron during
inflammation an adaptive response? How is hepcidin involved in all of this? What did the DRIVE study results show in terms of giving IV iron to patients with moderately elevated serum ferritin levels?
Singh: Glycosylate, pegylate ... what are the strategies to increase ESA half-life? Why does CERA have such a long half-life? How is EPO receptor affinity involved? What is HIF? How does it
affect EPO synthesis, and how do prolyl hydroxylase inhibitors affect HIF and EPO? How might hepcidin fit into this?
(more...)
|
Anemia Management in CKD: Improving Iron Management
John Reed, MD; Betsy Copeland, BSN, MSN, CFNP.
(ANNA National Symposium, Nashville, TN, April 2006.)
Reed: What is an evidence-based approach to iron therapy in non-dialysis CKD patients? What do the randomized controlled trials show when comparing oral with IV iron in non-dialysis CKD? What
is the prevalence of anemia in stage 2 through 4 CKD? What factors predict a response to oral or to IV iron treatment? What was our experience in setting up and managing a CKD clinic?
Copeland: What are the obstacles to success in treating iron deficiency in non-dialysis CKD? How did we do it? What helped in arranging timely referral? How did we find the time to give IV
iron in our daily practice? How do the various injection schedules for IV iron impact ease of treatment, cost, and time management? What is our protocol for doing this?
|
|
|
 |
|
The New KDOQI Guidelines for Anemia, a Debate: Should the Upper Hgb Limit be 12 or 13 g/dL? ASN Renal Week 2006
|
|
|
A New Tri-Partite Approach to Anemia ASN Renal Week 2006
|
|
|
Practical Considerations for the Management of Anemia in Nephrology Patients: Searching for an Improved Erythropoietic Treatment. RPA Satellite Symposium, 2006
|
|
Anemia in the PD Patient (Michael V. Rocco, MD, MS, FACP; Allen R. Nissenson, MD, FACP; Chaim Charytan, MD; David B. Van Wyck, MD) ADC 2006 (audio only)
|
|
|
Practical Considerations for the Management of Anemia in Nephrology Patients: Searching for an Improved Erythropoietic Treatment
(Pereira, Wish, Aronoff)
ANNA 2006
|
|
|
Anemia Management in CKD: Improving Anemia Management (target: nurses)
(Reed, Copeland)
ANNA 2006
|
|
|
Evidence-Based Anemia Management (target: nurses)
(McCarley)
ANNA 2006
|
|
|
A Balanced Approach to Anemia Therapy: IV Iron and EPO (target: nurses)
(Easom, Bowe)
ANNA 2006
|
|
New Developments in Anemia and Erythropoietin Science
(Ganz, Lin, Singh)
ASN Renal Week 2005 (audio only)
|
|
|
Anemia in Renal Disease: Update and Case Discussion
(Berns, Van Wyck)
ASN Renal Week 2005
|
|
|
The Role of Iron Deficiency in Anemia Management: Key Controversies
(Wish, Zager, Kalantar-Zadeh, Agarwal)
ASN Renal Week 2005
|
|
|
Anemia and Iron Management: Addressing Challenges and Generating Solutions (target: nurses)
(Easom, Volkert)
ANNA 2005
|
|
|
Complications of Anemia and the CKD Patient (target: nurses)
(Petroff)
ANNA 2005
|
|
|
Treating Patients With IV Iron Therapy: Special Considerations (target: nurses)
(Fishbane, Warady)
ANNA 2005
|
|
|
Maximizing Patient Outcomes Through IV Iron Therapy and Appropriate Iron
Measures
(Agarwal, Coyne)
RRI Sat 2005
|
|
 |
|
The target hemoglobin level in patients on dialysis (Singh AJ) Dial Transplant (Jul 2007)
|
|
|
Weighing the Hazards of Erythropoiesis Stimulation in Patients with Cancer (FR Khuri) N Engl J Med (Jun 2007)
|
|
|
Clinical aspects of iron use in the anemia of kidney disease JASN 02-07
|
|
|
Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR NDT (02-07)
|
|
|
(2006 Pharma )Year in Review (Michele B. Kaufman, PharmD, RPh) Dial-Transplant 12-06
|
|
|
| |
K-DOQI ANEMIA
GUIDELINES |
|
|
|
HDCN Topic
Pages (KEY) |
|
|
|
PRESCRIBING
INFO |
|
|
|
REIMBURSEMENT |
|
| | |
 |
Dr. Steve
Fishbane
Associate Professor of Medicine, Associate
Chairman, Department of Medicine, Winthop-University Hospital,
Mineola, NY
| | |
